ArticleRheumatology and therapy2022

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.

Gerd R Burmester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.